Governor Malloy recently announced, during his budget speech, that “Connecticut is open for business.”
Sadly, reality disagrees.
While Connecticut smarts over the loss of 1,100 jobs at Pfizer Inc.’s Groton research facility, Massachusetts will end up on the winning side, gaining hundreds of coveted, often highly paid drug research jobs.
As the pharmaceutical giant moves neuroscience and cardiovascular research units to Cambridge, Mass., it expects to create 450 jobs in the Bay State and eliminate about 100, for a gain of 350 positions there, a senior Pfizer research executive said Wednesday.
Just for the record, what sort of jobs are these?
The workers include scientists, chemists, biologists and technicians — and are jobs that are seen as crucial not only to Connecticut’s current economic recovery but its future as a center for biotech research and development.
The real kicker is, that opposed to Governor Malloy’s “First Five” initiative…
“A Pfizer spokeswoman said Massachusetts did not kick in any financial incentives that influenced the move.”
When a company moves its operations to the city of Cambridge, aka the People’s Republic of Cambridge, you’re not “open for business.” You’re not even playing for keeps.